Watch More Highlights

Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses an update on treating Richter Syndrome, including information on clonally related vs unrelated variants of the disease; the role of venetoclax, acalabrutinib, pirtobrutinib, and DA-EPOCH-VR chemotherapy; and the use of immune checkpoint inhibitors and CAR T-cell therapy; as well as a number of ongoing clinical trials on combinations of various targeted agents.

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.